Farber; Lothar

Patent Applications and Registrations

Patent applications and USPTO patent grants for Farber; Lothar.The latest application filed is for "rapamycin derivative or an impdh inhibitor for treating polycystic kidney disease".

Company Profile

0.2.14

Farber; Lothar - Heroldsberg DE
FARBER; Lothar - Horoldsberg DE
Farber; Lothar - Haroldsberg DE
Farber; Lothar - 90562 Heroldsberg DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Rapamycin Derivative or an Impdh Inhibitor for Treating Polycystic Kidney Disease App 20140135324 - Farber; Lothar ; et al.	2014-05-15
Rapamycin Derivative or an Impdh Inhibitor for Treating Polycystic Kidney Disease App 20120220619 - FARBER; Lothar ; et al.	2012-08-30
Rapamycin Derivative or an Impdh Inhibitor for Treating Polycystic Kidney Disease App 20110136852 - Farber; Lothar ; et al.	2011-06-09
Pharmaceutical uses Grant 7,713,984 - Farber , et al. May 11, 2	2010-05-11
Method of Treating Fibromyalgia or Associated Functional Symptoms of Fibromyalgia App 20100055176 - Farber; Lothar ; et al.	2010-03-04
Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract App 20090041775 - Adam; Hansjorg ; et al.	2009-02-12
Rapamycin Derivative or an Impdh Inhibitor For Treating Polycystic Kidney Disease App 20080280940 - Farber; Lothar ; et al.	2008-11-13
Pharmaceutical uses App 20080161329 - Farber; Lothar ; et al.	2008-07-03
Pharmaceutical uses App 20070155759 - Farber; Lothar ; et al.	2007-07-05
Use of cd25 binding molecules in the treatmnet of inflammatory diseases of the gastrointestinal tract App 20050226872 - Adam, Hansjorg ; et al.	2005-10-13
Use of 5-HT3 receptor antagonists for the treatment of inflammations of the respiratory tract App 20050197323 - Farber, Lothar ; et al.	2005-09-08
Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome App 20050096334 - Farber, Lothar ; et al.	2005-05-05
Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome App 20030092735 - Farber, Lothar ; et al.	2003-05-15
Use of 5-HT (3) receptor antagonists for treating musculoeskeletal diseases App 20030008809 - Muller, Wolfgang ; et al.	2003-01-09
Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes Grant 6,384,042 - Farber , et al. May 7, 2	2002-05-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.